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Abstract In an effort to identify novel genes implicated in breast carcinogenesis, a genomewide scan for loss
of heterozygosity (LOH) and copy number changes in paired-DNA samples extracted from normal
and tumor tissue of frozen sections from women undergoing surgery for invasive breast cancer was
conducted. The Affymetrix 10K SNP array was used to examine genomewide LOH of chromo-
somal regions. The number of LOH events, number of informative loci, percent heterozygosity,
and percent fractional allelic loss (%FAL) were calculated. Although LOH events were detected
in all samples, the proportion of LOH ranged from 0.1 to 57.2%. Elevated LOH events were de-
tected in two samples, with a %FAL of 57.2 and 56.2. Chromosomal regions exceeding a threshold
value for a P-value curve based on multiple-testing adjusted permutation methods were identified as
significant regions of shared LOH across samples. Regions with significant LOH included 2p25.3;
2p21; 2p15~p16.1, 2q23.3; and, 16q12.1. Chromosomal region 1q32.1 was identified as a region
with significant copy number amplification. Regions of LOH and copy number changes identified
from this analysis may provide insights into the underlying processes of and genes involved in
breast carcinogenesis. The present study demonstrates a feasible methodological approach for
the assessment of LOH and copy number changes.
 2008 Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction
Carcinogenesis is a process characterized by genetic
instability [1]. Loss of heterozygosity (LOH) and chromo-
somal amplification are important mechanisms involved in
carcinogenesis [2], including breast carcinogenesis [3,4].
Chromosomal regions exhibiting LOH may contain tumor
suppressor genes. A vast number of studies have conducted
LOH analysis in breast cancer [4]. In recent years, the use
of high density single nucleotide polymorphism (SNP)-
based microarray technology has lead to genomewide in-
vestigations of LOH, permitting the investigation of all
chromosomes simultaneously with denser marker spacing
and thus improving the resolution of the analysis.
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Open access under CC BY-NC-ND licenseJa¨nne et al. [5] demonstrated the efficiency and reliabil-
ity of the 10K Mapping SNP array in their study comparing
this platform to a previous generation array containing
~1,500 SNPs, as well as to single-sequence length polymor-
phism methods. Although SNP allelotyping technology has
been applied successfully to other cancer types [6e8], we
know of only one previous published study that examined
LOH in breast cancer, using an early version of this tech-
nology [3]. Wang et al. [3] examined the LOH profile of
34 invasive breast carcinomas using the HuSNP chip (Affy-
metrix, Santa Clara, CA), containing 1,494 SNP loci with
an average of 2.57 cM between each SNP marker. Regions
17p, 17q, 16q, 11q, and 14q were identified as the most
common LOH sites.
In the present study, we examined LOH events and copy
number change of chromosomes using DNA extracted from
microdissected normal and tumor tissue of frozen sections
.
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Although studies have demonstrated that the use of DNA
extracted from formalin-fixed tissue is feasible [9], fresh-
frozen samples are the most optimal source of DNA for
these analyses. We used the Affymetrix 10K Mapping
SNP array, containing ~11,500 SNPs, to identify genome-
wide LOH and amplification of chromosomal regions.
Regions identified from this analysis may provide insights
into the underlying processes of and genes involved in
breast carcinogenesis.
2. Materials and methods
2.1. Study population
The study population comprised 16 women undergoing
surgery for invasive breast cancer at Columbia University
Medical Center (New York, NY). Paired normal and tumor
tissue were microdissected from fresh-frozen sections
available from the Avon Foundationesupported macromol-
ecule bank of the Herbert Irving Comprehensive Cancer
Center and were confirmed by histology at the Department
of Pathology at Columbia University.
2.2. Affymetrix GeneChip protocol
Genomic DNA was extracted from paired, microdis-
sected normal and tumor tissue. DNA samples were nor-
malized at 50 ng/mL concentration using reduced TE
buffer (10 mmol/LTris-HCl, pH 8, and 0.1 mmol/L EDTA).
Quantification was assessed from 1 mL of sample using an
ND1000 spectrophotometer (NanoDrop, Wilmington, DE);
quality was assessed in duplicate from 1 mL of sample per
well using DNA7500 chip with a BioAnalyzer 2100 (Agi-
lent Technologies, Santa Clara, CA). Major peaks were
seen atO3 kb in size. For each GeneChip, 250 ng of geno-
mic DNA sample was digested with XbaI restriction
enzyme and maintained at 4C. Adaptor Xba was then
ligated to the digested DNA and stored at 20C until
PCR amplification.
For amplification, diluted adaptor-ligated DNAwas used
as template and universal primer (10 mmol/L; Affymetrix)
was used along with dNTPs and Amplitaq Gold DNA poly-
merase (Applied Biosystems, Foster City, CA). PCR reac-
tion was conducted using a PTC 100 Peltier thermal
cycler (MJ Research, Watertown, MA) using denaturation
at 95C for 3 minutes, followed by 35 cycles at 95C for
20 seconds, 59C for 15 seconds, and 72C for 15 seconds,
followed by final extension at 72C for 7 minutes. PCR
product was checked using DNA1000 chip in the Agilent
Bioanalyzer 2100.
PCR product was purified and concentrated with
QIAquick PCR Purification kit (Qiagen, Valencia, CA).
PCR product was quantified using the ND1000 spectropho-
tometer. Subsequently, 20 mg of PCR product in 45 mL vol-
ume was used for fragmentation. PCR product quality waschecked on a DNA1000 chip with a Agilent Bioanalyzer
2100.
Typical electropherograms of 12 purified PCR products
are shown in Figure 1. Fragmentation was done using frag-
mentation reagent (Affymetrix). For QC purpose, 1 mL of
1:10 dilution of fragmented DNA sample was put on
DNA1000 chip read by Agilent 2100 Bioanalyzer. The ma-
jor peak of the electropherogram was seen at 15 to 50 bp
(Fig. 2). The fragmented PCR products were labeled with
GeneChip DNA labeling reagent (Affymetrix) by adding
19.4 mL of labeling master mix with 50.6 mL of fragmented
DNA to make 70 mL reaction volume in 0.2 mL PCR tube.
The sample was incubated at 37C for 2 hours, followed by
heat deactivation at 95C for 15 minutes, and the was im-
mediately transferred on ice. This 70 mL of labeled DNA
was mixed with 190 mL of hybe cocktail in a 1.5-mL Ep-
pendorf tube. The samples were denatured at 95C for 10
minutes, then the tubes were transferred to ice for exactly
10 seconds. The target DNA was placed on heating block
at 48C for 2 minutes, after which 200 mL of the denatured
hybridization sample was injected into the probe array.
Hybridization was done at 48C for 16e18 hours at 60 rev-
olutions per minute. Thereafter, staining and washing was
performed, followed by scanning with high-resolution
Affymetrix GeneChip scanner 3000.
2.3. Statistical analysis
The number of LOH events, number of informative loci,
percent heterozygosity, and percent fractional allelic loss
were calculated. SNP calls of paired normal and tumor
samples were combined to make LOH calls, as described
by Lin et al. [10]. Briefly, LOH events were identified when
the normal sample at a particular marker was heterozygous
(AB) and the tumor sample at the same marker was either
A or B. The fractional allelic loss (FAL) was calculated as
the number of LOH events per number of informative loci.
Regions of shared LOH across samples were identified by
a P-value curve based on multiple-testing adjusted permu-
tation methods as described by Lin et al. [10]. The signifi-
cance curve was used to identify significant shared LOH
regions across samples exceeding the threshold value
0.25 [10,11]. Additionally, we also performed copy number
analysis of DNA. Arrays were normalized for probe signal
intensity and a signal value was computed for each SNP.
The raw copy number for each SNP was computed as twice
the ratio of the signal to the mean signal of normal samples
at this SNP. A hidden Markov model (HMM) was used to
infer copy numbers, as been described by Zhao et al.
[12]. All statistical analyses were performed using the
dChipSNP module [10] of dChip software [13].
3. Results
Sixteen female breast cancer cases were included in the
present study. The demographic and clinical characteristics
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major amplicons ranging between 700 and 1,000 bp. FU, fluorescence unit; S, time in seconds.of the study population are given in Table 1. The majority
of women were white, with an average age at diagnosis of
58.4 years. The majority of tumors were estrogen receptor
positive (ERþ) or progesterone receptor positive (PRþ),
with 10 of the cases (71.4%) positive for both. Approxi-
mately 43% of tumors were positive for ERBB2 (alias
HER2/neu). Most tumors were grade 2 or 3.
The average genotype call rates for tumor and normal
samples were 92.8% 6 2.9% and 92.4% 6 7.3%,
respectively. On average, 3,324 loci were informative,
corresponding to a heterozygosity of ~29.7%.
Table 2 presents the LOH findings for the paired sam-
ples. LOH events were detected in all samples; however,the proportion of LOH ranged from 0.1 to 57.2%. This
range is consistent with findings from other studies for
breast cancer [3,14]. In particular, elevated LOH events
were detected in samples 1 and 10, with a %FAL of 57.2
and 56.2, respectively.
Several regions of significant LOH were detected, partic-
ularly 2p25.3, 2p21, 2p15~p16.1, 2q23.3, and 16q12.1. All
known genes contained within these regions are listed in
Table 3. There was no clustering of %FAL by patient charac-
teristics including stage, grade, PR status, ER status, ERBB2
(HER2/neu) status, family history, or race.
In our analyses of chromosomal copy number variation,
the 1q32.1 region was identified as a significant region ofFig. 2. Electropherogram of 12 fragmented PCR products overlaid against DNA marker (in yellow) shows uniform pattern of fragmentation: the fragments
range between throughout the samples ranging between 15 and 50 bp in size throughout the samples.
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chromosomal regions exhibited evidence of copy number
variations, changes were less consistently seen across the
samples than for 1q (Fig. 3).
4. Discussion
The present study demonstrated the feasibility and util-
ity of using fresh-frozen tissue for the examination of
LOH using microarray technology. The Affymetrix Gene-
Chip Human Mapping 10K Array Xba 131 was used to per-
form genomewide LOH and copy number change analyses
of 16 breast cancer samples using 11,205 SNPs. Frequent
allelic loss was seen on chromosomes 2p, 2q, and 16q.
LOH on chromosome 2 has been infrequently reported in
the literature on allelic loss in breast cancer based on
traditional methods of LOH analyses.
In the present study, significant chromosomal loss was
found at 2p. This finding for breast cancer has been
reported from only a few studies [15,16]. Additionally, we
see chromosomal loss at 2q. Loss at this region was reported
by Piao et al. [17] and in a pooled analysis byMiller et al. [4],
who showed that loss in region 2q was strong in spite of com-
paratively few observations. Osborne and Hamshere [18]
also demonstrated loss at the 2q region by incorporating data
across studies. One explanation for this infrequent finding is
that the spacing of markers in this chromosomal region may
Table 1
Selected clinical and demographic characteristics of study participants
Characteristic Value
Female, no. (%) 16 (100)
Mean age at diagnosis in years, yr (SD) 58.4 (11.0)
Race, no. (%)
White/Non-Hispanic 14 (87.5)
Hispanic 1 (6.25)
Other/Unknown 1 (6.25)
Family history of breast cancer, no. (%)
Yes 7 (43.7)
No 9 (56.3)
ER status, no. (%)
Positive 14 (87.5)
Negative 2 (12.5)
PR status, no. (%)
Positive 10 (62.5)
Negative 6 (37.5)
TNM Stage, no. (%)
I 6 (37.5)
II 6 (37.5)
III 4 (25.0)
IV d
ERBB2, no. (%)
Positive 6 (42.9)
Negative 8 (57.1)
Grade, no. (%)
1 2 (12.5)
2 7 (43.8)
3 6 (37.5)
Not determined 1 (6.2)
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; SD,
standard deviation.have been too sparse for previous studies to detect loss in the
region. Additionally, LOH at the 2q region could be associ-
atedwith a subtype or clinical characteristic that has not been
sufficiently prevalent within all studies.
Significant chromosomal loss was also found at 16q.
Previous studies indicate that loss in this chromosomal
arm typically falls among the highest loss rates [14,19].
Additionally, pooled analyses by Miller et al. [4] and Os-
borne and Hamshere [18] demonstrated significant LOH
in this chromosomal region.
Several of the genes contained within the regions of
significant LOH in the present study have been previously
implicated in carcinogenesis. Although the present study
investigated a small sample and inference from these find-
ings is somewhat limited, several potential candidate genes
of interest have been identified which should be further ex-
amined, including PRKCE, FANCL, BCL11A, and SALL1.
Chromosomal amplification was detected in region
1q32.1. Amplification of this region has been previously
reported for both breast cancer and other cancers [20,21]. Ex-
amination of genes contained within region 1q32.1 shows
that it is a very gene-rich region, containing ~60 known
genes. Region 1q32.1 has been identified as a region of geno-
mic amplification in other studies of carcinogenesis. Corson
et al. [20] detected amplification of chromosomal region
1q32.1 in retinoblastoma and observed the overexpression
of KIF14, located at 1q32.1, in breast cancer cell lines, pri-
mary retinoblastoma, lung cancer cell lines, and medullo-
blastoma. Additionally, SRGAP2 (alias KIAA0456; also
known as FNBP2 or srGAP3) is also located at chromosomal
region 1q32.1. The SRGAP2 gene was observed to be ampli-
fied and overexpressed in breast cancer cell lines [22]. Addi-
tionally, SRGAP2was overexpressed inmelanoma, germ cell
tumors, chondrosarcoma, and retinoblastoma [22].
Table 2
Loss of heterozygosity (LOH) events from normal and tumor DNA pairs
Sample LOH events,
no.
Informative
loci, no.
Heterozygosity,
%
FAL
(%)
1 1,984 3,466 30.9 57.2
2 57 3,151 28.1 1.8
3 9 3,319 29.6 0.3
4 4 3,658 32.6 0.1
5 17 3,380 30.2 0.5
6 35 3,450 30.8 1.0
7 24 3,423 30.5 0.7
8 66 2,809 25.1 2.3
9 65 3,668 32.7 1.8
10 2,073 3,686 32.9 56.2
11 5 3,794 33.9 0.1
12 300 2,754 24.6 10.9
13 97 3,346 29.9 2.9
14 49 2,870 25.6 1.7
15 75 3,527 31.5 2.1
16 111 2,890 25.8 3.8
The total number of mapped loci was 11,205. Percent heterozygosity5
No. of informative loci/No. of mapped loci  100. Percent fractional
allelic loss FAL% 5 No. of LOH/No. of informative loci  100.
Abbreviations: LOH, loss of heterozygosity.
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Known genes contained within regions of LOH
LOH Cytoband Accession no. Gene symbol Gene description
2p25.3
NM_015025 MYT1L myelin transcription factor 1-like
NM_002936 RNASEH1 ribonuclease H1
NM_001011 RPS7 ribosomal protein S7
NM_024027 COLEC11 collectin sub-family member 11
NM_199232 ALLC allantoicase
2p21
NM_005400 PRKCE protein kinase C, epsilon
2p15-p16
NM_006296 VRK2 vaccinia related kinase 2
NM_018062 FANCL Fanconi anemia, complementation group L
NM_018014 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein)
NM_022894 PAPOLG poly(A) polymerase gamma
NM_002908 REL v-rel reticuloendotheliosis viral oncogene homolog
NM_144709 PUS10 pseudouridylate synthase 10
NM_002618 PEX13 peroxisome biogenesis factor 13
NM_032506 KIAA1841 KIAA1841
NM_152392 AHSA2 AHA1, activator of heat shock 90kDa protein ATPase homolog 2
NM_014709 USP34 ubiquitin specific peptidase 34
2q23.3
XM_371575 PRPF40A PRP40 pre-mRNA processing factor 40 homolog A
NM_152522 ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6
16q12.1
NM_002968 SALL1 sal-like 1The two samples with elevated FAL were from (1)
a woman with a stage 3 and grade 3 tumor, negative for both
ER and PR status, ERBB2 positive, and no family history of
breast cancer and (2) a woman with a stage 1 and grade 1 tu-
mor, positive for both ER andPR status,ERBB2 negative, and
a family history of breast cancer. Given the sample size of the
present study, we were not powered to examine associations
of clinical characteristics with LOH or copy number change.However, this is an important aspect thatwe plan to address in
future studies with a larger sample.
5. Conclusions
In summary, regions of frequent allelic loss detected in
breast cancer in this microarray-based genomewide study
included 2p25.3, 2p21, 2p15~p16.1, 2q23.3, and, 16q12.1.Fig. 3. Copy number summary plot for all samples shows the proportion of samples with copy number amplification to at least 3 copies in red and copy
number reduction to 1 copy or less in blue.
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somal amplification. The findings from the present study
are consistent with previous studies of LOH and copy
number change in breast cancer based on more traditional
analyses. Regions of LOH and amplification identified from
this analysis may provide insights into the underlying pro-
cesses of and genes involved in breast carcinogenesis. This
pilot work also demonstrates the utility and feasibility of
microarray SNP chips for identifying novel loci involved
in breast cancer.
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